AdvaMed 2011 is the premier MedTech Conference for CEOs, business executives, policy-makers, financiers, media, and industry stakeholders from around the world. Previously OneMedRadio interviewed Ken Mendez, AdvaMed’s Chief Administrative Officer and gained some incredible insight into what one can expect from the conference taking place September 26-28 at the Walter E. Washington Convention Center in Washington, D.C.
In addition to educational panels featuring thought-leaders that will discuss important issues and keynote addresses from internationally respected voices, the conference will also feature over 70 company presentations. Below are some interesting technologies attendees can expect to hear from:
Soft Tissue Regeneration, Inc. is a privately held medical device company defining new technology for the soft tissue regeneration segment of the sports medicine market. The company has developed and tested a breakthrough biodegradable scaffold for regeneration of the anterior cruciate ligament (ACL) of the knee and for the first time, has regenerated a native, natural ACL. Joseph W. Reilly, President and Chief Executive Officer of Soft Tissue Regeneration, Inc, will present at AdvaMed 2011 on September 27, 2011 at 10:30.
GlySure has developed a continuous glucose monitoring system using an intravascular, optical fluorescence-based sensor to support clinical implementation of Tight Glycemic Control and Intensive Insulin Therapy. The one consistent area of agreement between leaders in the field of glycemic control is the need for easier, more effective glycose monitoring in the ICU. Glysure will present their technology on September 27, 2011 at 3:30.
Wound Management Technologies [PINK:WNDM] is an emerging commercial stage company with its primary products in the $5B worldwide advanced wound care market. Wound Management’s primary focus is the distribution of its unique, patented collagen product, CellerateRX, which is FDA cleared and reimbursable under Medicare. The company will present on September 28, 2011 at 9:10.
CytoSorbents [OTC:CTSO] is a healthcare company in the medical device field that has developed a new hemoperfusion technology for removing toxins from the blood associated with sepsis, kidney disease, and other diseases. The company received European CE Mark approval for its flagship product, CytoSorb, earlier this year. They will present on September 27, 2011 at 3:20.
The aforementioned companies can also be seen at OneMedForum SF 2012 in San Francisco, January 9-12, 2012 at the Sir Francis Drake Hotel. For a full list of AdvaMed presenting companies, please visit www.advamed2011.com.